Shares of Biocon rose 2% on Tuesday, hitting the day’s high of Rs 399 on NSE after the company secured a 10-year supply contract for Pertuzumab in Brazil for breast cancer therapy.
According to a filing with the exchange, the company said it signed a partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil, marking an important milestone in advancing production and commercialisation of the HER2-positive breast cancer therapy under the country’s Productive Development Partnership (PDP) program.